Form 4: Blueprint Medicines Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Fouad Namouni, President of R&D at Blueprint Medicines, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On October 3, 2024, Fouad Namouni, President of R&D at Blueprint Medicines Corp, sold 3,633 shares of common stock at an average price of $89.32.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, Namouni directly owns 69,070 shares of Blueprint Medicines Corp.
- The sale was not a discretionary trade but an automatic 'sell to cover' transaction to satisfy tax obligations.
Sentiment
Score: 5
Explanation: The Form 4 filing represents a routine transaction (sell to cover taxes) and does not inherently indicate positive or negative sentiment regarding the company's prospects.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives.
Key Dates
| Date | Description |
|---|---|
| 10/03/2024 | Date of stock sale transaction |
| 10/04/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.